Effect of Food on Pharmacokinetics of IN-A002 in Healthy Males

Phase 1, randomised, open-label trial of CJ-15314 in rheumatoid arthritis (RA) and atopic dermatitis (AD) (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration (Cmax) of IN-A002 up to 72 hours and Area Under the Curve to the Last Quantifiable Concentration (AUClast) of IN-A002 up to 72 hours. Status: unknown.